NCT07272837Recruiting
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 26 Nov 2025
- Start date
- 15 May 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Alberta
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07272837
What you commit to
- Study type: Observational
- Planned participants: 50
- From 15 May 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
Other illness
- Major recent heart issues or other severe health conditions
Other
- Current use of semaglutide for more than 2 weeks
- Dependence on a mobility aid (unable to participate in exercise MRI)
Who the study is looking for
- Adults 18-80 years of age
- Starting semaglutide for type 2 diabetes or weight loss
- Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mazankowski Alberta Heart Institute Coordinator of this site? Confirm its status | Edmonton | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.